MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Core Insights - MannKind Corporation will present data on inhaled insulin at the 18th International Conference on Advanced Technologies and Treatments for Diabetes in Amsterdam from March 19-22, 2025 [1][2] Group 1: Study Presentations - The conference will feature five presentations related to inhaled insulin, including topics such as the efficacy of inhaled insulin in pediatric and adult populations [2][3] - Dr. Kevin Kaiserman emphasized the importance of Afrezza as a treatment option for adults with diabetes, particularly for those using multiple daily injections (MDI) and automated insulin delivery (AID) systems [2] - Specific presentations include the INHALE-1 pediatric study and the INHALE-3 adult study, showcasing sustained benefits and comparisons with usual care [3][4] Group 2: Study Details - The INHALE-1 study is a Phase 3 trial involving 230 pediatric subjects aged 4-17, comparing inhaled insulin with multiple daily injections over a 26-week period [6] - The INHALE-3 study involved 141 adult participants, assessing the efficacy of inhaled insulin combined with basal insulin versus standard care over a 17-week period [7][8] - Both studies reported positive outcomes, with the INHALE-3 study meeting its primary efficacy endpoint of non-inferior change in HbA1c levels [9] Group 3: Company Overview - MannKind Corporation focuses on developing inhaled therapeutic products for endocrine and orphan lung diseases, utilizing advanced formulation and device engineering [12][13] - The company aims to address unmet medical needs through innovative delivery methods, particularly for conditions like diabetes and pulmonary diseases [13][14]